Browsing by Author "Baken, Kirsten"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- HBM4EU - Deliverable Report D 6.2. Revised set of key indicatorsPublication . Reynders, Hans; Van Campenhout, Karen; Mampaey, Maja; Gilles, Liese; Colles, Ann; Baken, Kirsten; Bessems, Jos; Schoeters, Greet; Ay, Derya; Lobo Vicente, Joana; Ganzleben, Catherine; Isidro, Glória; Louro, Henriqueta; Silva, Maria João; Uhl, Maria; Ubong, Dorothy; Sepai, Ovnair; Tarroja, Elena; Persoz, Charles; Barouki, Robert; Kobosil, Nicole; David, Madlen; Appel, Petra; Kolossa, Marike; Coertjens, Dries; Crabbé, Ann; Loots, Ilse; Covaci, Adrian; Antignac, Jean-Philippe; Debrauwer, Laurent; Fernandez, Mariana; Berglund, Marika; Blaha, Ludek; Esteban López, Marta; Scheepers, Paul; Tolonen, Hanna; Nørager., SofieThe current deliverable describes the process of revision of the first list of indicators (published in June 2017 as D6.1.) and presents the indicator leaflets ((see attachment 1) that link key results of HBM4EU to the objectives of the project as laid down in the description of action. These indicator leaflets already contain a lot of results on the revised list of indicators, and give very valuable information on the progress of HBM4EU in relation to the specific goals of the project. Combining the information from these leaflets in the frame of expected impacts will allow us to put forward conclusions towards impact and sustainability of HBM4EU. As such, this restructured list answers to the main comments on the first list of indicators from the task 6.5 partners, the Management Board, the Governing Board and the EU Policy Board, in concretu to: • Drastically reduce the number of indicators from 48 indicators (including 9 internal indicators) on the first list to 28 indicators on the revised list without losing essential information. Moreover by bundling related indicators we now have 22 indicator leaflets (and 1 overview leaflet); • Make the relationship between the indicators and the goals of HBM4EU more clear by structuring the list of indicators according to the overarching objectives and specific goals; • Use the indicators to say something about the impact of the HBM4EU project: the indicator leaflets were used to give input for the impact section of the periodic technical reporting 2018 to describe the progress made for the 5 expected impacts of HBM4EU. This exercise will be continued and ameliorated in the 2019 periodic technical reporting as more indicator leaflets will be available compared to 2018; • Link the indicators with the work on sustainability of HBM in Europe: the indicators were presented at the sustainability workshop in Paris. Participants indicated that they think the leaflets will be useful for institutional discussions, national hub meetings, meetings with policy makers and other meetings and that they would like to use them as soon as they are available. The added value of having indicators of success, is to monitor the implementation and achieved impact of HBM4EU. This will allow for a more efficient tracking of achieved goals. This deliverable will help to further optimize and revise the first set of indicators to monitor the implementation of the HBM4EU and the achieved impact. The indicators of success are written in a clear language, they are concise and capture the main achievements in the list of indicators that has been agreed amongst the partners. Therefore, they can be easily used by all partners across the consortium, the EU Policy Board and our HBM4EU ambassador Thomas Jackl.
- Implementation of effect biomarkers in human biomonitoring studies: A systematic approach synergizing toxicological and epidemiological knowledgePublication . Rodríguez-Carrillo, Andrea; Mustieles, Vicente; Salamanca-Fernández, Elena; Olivas-Martínez, Alicia; Suárez, Beatriz; Bajard, Lola; Baken, Kirsten; Blaha, Ludek; Bonefeld-Jørgensen, Eva Cecilie; Couderq, Stephan; D'Cruz, Shereen Cynthia; Fini, Jean-Baptiste; Govarts, Eva; Gundacker, Claudia; Hernández, Antonio F.; Lacasaña, Marina; Laguzzi, Federica; Linderman, Birgitte; Long, Manhai; Louro, Henriqueta; Neophytou, Christiana; Oberemn, Axel; Remy, Sylvie; Rosenmai, Anna Kjerstine; Saber, Anne Thoustrup; Schoeters, Greet; Silva, Maria João; Smagulova, Fatima; Uhl, Maria; Vinggaard, Anne Marie; Vogel, Ulla; Wielsøe, Maria; Olea, Nicolás; Fernández, Mariana F.Human biomonitoring (HBM) studies have highlighted widespread daily exposure to environmental chemicals. Some of these are suspected to contribute to adverse health outcomes such as reproductive, neurological, and metabolic disorders, among other developmental and chronic impairments. One of the objectives of the H2020 European Human Biomonitoring Initiative (HBM4EU) was the development of informative effect biomarkers for application in a more systematic and harmonized way in large-scale European HBM studies. The inclusion of effect biomarkers would complement exposure data with mechanistically-based information on early and late adverse effects. For this purpose, a stepwise strategy was developed to identify and implement a panel of validated effect biomarkers in European HBM studies. This work offers an overview of the complete procedure followed, from comprehensive literature search strategies, selection of criteria for effect biomarkers and their classification and prioritization, based on toxicological data and adverse outcomes, to pilot studies for their analytical, physiological, and epidemiological validation. We present the example of one study that demonstrated the mediating role of the effect biomarker status of brain-derived neurotrophic factor BDNF in the longitudinal association between infant bisphenol A (BPA) exposure and behavioral function in adolescence. A panel of effect biomarkers has been implemented in the HBM4EU Aligned Studies as main outcomes, including traditional oxidative stress, reproductive, and thyroid hormone biomarkers. Novel biomarkers of effect, such as DNA methylation status of BDNF and kisspeptin (KISS) genes were also evaluated as molecular markers of neurological and reproductive health, respectively. A panel of effect biomarkers has also been applied in HBM4EU occupational studies, such as micronucleus analysis in lymphocytes and reticulocytes, whole blood comet assay, and malondialdehyde, 8-oxo-2′-deoxyguanosine and untargeted metabolomic profile in urine, to investigate, for example, biological changes in response to hexavalent chromium Cr(VI) exposure. The use of effect biomarkers in HBM4EU has demonstrated their ability to detect early biological effects of chemical exposure and to identify subgroups that are at higher risk. The roadmap developed in HBM4EU confirms the utility of effect biomarkers, and support one of the main objectives of HBM research, which is to link exposure biomarkers to mechanistically validated effect and susceptibility biomarkers in order to better understand the public health implications of human exposure to environmental chemicals.